Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study.
Child–Turcotte–Pugh
cirrhosis
hepatocellular carcinoma
insulin-like growth factor-1
Journal
Journal of hepatocellular carcinoma
ISSN: 2253-5969
Titre abrégé: J Hepatocell Carcinoma
Pays: New Zealand
ID NLM: 101674775
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
05
2020
accepted:
14
08
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
29
9
2020
Statut:
epublish
Résumé
The Child-Turcotte-Pugh score (CTP) is the most commonly used tool to assess hepatic reserve and predict survival in hepatocellular cancer (HCC). The CTP stratification accuracy has been questioned and attempts have been made to improve the objectivity of the system. Serum insulin-like growth factor-1 (IGF-1)-CTP has been proposed to improve CTP prognostic accuracy. We aimed to validate the IGF-CTP score in our patient population. A total of 84 diagnosed HCC patients were enrolled prospectively. IGF-CTP scores in addition to CTP scores were calculated. C-index was used to compare the prognostic significance of the two scoring systems and overall survival (OS). Cirrhosis was present in 48 (57.1%) patients, 35 (41.7%) patients were non-cirrhotic, 36 (42.8%) patients were hepatitis B (HBV) positive, and 8 (9.5%) patients were hepatitis C (HCV) positive. Serum IGF-1 levels were significantly lower in cirrhotic compared with non-cirrhotic patients (p=0.04). There was a significant difference in OS rates of patients with serum IGF-1 level <50 ng/mL and patients with serum IGF-1 levels ≥50 ng/mL (p=0.02); the OS rates were 6.5 and 14.8 months, respectively (p=0.02). The median OS of all patients was 7.38 months (95% CI: 5.89-13.79). The estimated C-index for CTP and IGF-CTP scores was 0.605 (95% CI: 0.538, 0.672) and 0.599 (95% CI: 0.543, 0.655), respectively. The U statistics indicated that the C-indices between two scoring systems are not statistically different (P= 0.91). This study evaluated IGF-1 levels and the IGF-CTP classification in a predominantly HBV (+) cohort of HCC patients with 41.7% non-cirrhotic. Although the prognostic value was similar, among patients with CTP-A, class those reclassified as IGF-CTP B had shorter OS than those with IGF-CTP score A. Thus, further validations of IGF-CTP score in similar populations may add additional value as a stratification tool to predict HCC outcome.
Sections du résumé
BACKGROUND
BACKGROUND
The Child-Turcotte-Pugh score (CTP) is the most commonly used tool to assess hepatic reserve and predict survival in hepatocellular cancer (HCC). The CTP stratification accuracy has been questioned and attempts have been made to improve the objectivity of the system. Serum insulin-like growth factor-1 (IGF-1)-CTP has been proposed to improve CTP prognostic accuracy. We aimed to validate the IGF-CTP score in our patient population.
PATIENTS AND METHODS
METHODS
A total of 84 diagnosed HCC patients were enrolled prospectively. IGF-CTP scores in addition to CTP scores were calculated. C-index was used to compare the prognostic significance of the two scoring systems and overall survival (OS).
RESULTS
RESULTS
Cirrhosis was present in 48 (57.1%) patients, 35 (41.7%) patients were non-cirrhotic, 36 (42.8%) patients were hepatitis B (HBV) positive, and 8 (9.5%) patients were hepatitis C (HCV) positive. Serum IGF-1 levels were significantly lower in cirrhotic compared with non-cirrhotic patients (p=0.04). There was a significant difference in OS rates of patients with serum IGF-1 level <50 ng/mL and patients with serum IGF-1 levels ≥50 ng/mL (p=0.02); the OS rates were 6.5 and 14.8 months, respectively (p=0.02). The median OS of all patients was 7.38 months (95% CI: 5.89-13.79). The estimated C-index for CTP and IGF-CTP scores was 0.605 (95% CI: 0.538, 0.672) and 0.599 (95% CI: 0.543, 0.655), respectively. The U statistics indicated that the C-indices between two scoring systems are not statistically different (P= 0.91).
CONCLUSION
CONCLUSIONS
This study evaluated IGF-1 levels and the IGF-CTP classification in a predominantly HBV (+) cohort of HCC patients with 41.7% non-cirrhotic. Although the prognostic value was similar, among patients with CTP-A, class those reclassified as IGF-CTP B had shorter OS than those with IGF-CTP score A. Thus, further validations of IGF-CTP score in similar populations may add additional value as a stratification tool to predict HCC outcome.
Identifiants
pubmed: 32984091
doi: 10.2147/JHC.S258930
pii: 258930
pmc: PMC7502406
doi:
Types de publication
Journal Article
Langues
eng
Pagination
143-153Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2020 Lacin et al.
Déclaration de conflit d'intérêts
The authors have no commercial associations of support that might pose a conflict of interest. The authors report no conflicts of interest for this work.
Références
J Hepatol. 2008 Jul;49(1):34-42
pubmed: 18456366
Oncotarget. 2015 Aug 28;6(25):21193-207
pubmed: 26098859
HPB (Oxford). 2010 Jun;12(5):289-99
pubmed: 20590901
J Natl Cancer Inst. 2014 May 09;106(5):
pubmed: 24815863
Lancet. 1998 May 9;351(9113):1393-6
pubmed: 9593409
J Natl Cancer Inst. 1999 Jan 20;91(2):151-6
pubmed: 9923856
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
BMC Cancer. 2018 Jul 31;18(1):774
pubmed: 30064393
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Br J Cancer. 1992 Mar;65(3):311-20
pubmed: 1313689
J Hepatocell Carcinoma. 2015 Sep 18;2:131-42
pubmed: 27508202
Liver Transpl. 2002 Sep;8(9):851-8
pubmed: 12200791
J Natl Cancer Inst. 1999 Apr 7;91(7):620-5
pubmed: 10203281
Nat Rev Cancer. 2008 Dec;8(12):915-28
pubmed: 19029956
Science. 1998 Jan 23;279(5350):563-6
pubmed: 9438850
Int J Mol Sci. 2017 Jul 05;18(7):
pubmed: 28678199
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
J Clin Oncol. 2011 Oct 10;29(29):3892-9
pubmed: 21911725
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Oncotarget. 2017 Jul 12;8(46):81098-81108
pubmed: 29113370
PLoS One. 2017 Jan 20;12(1):e0170394
pubmed: 28107416
Turk J Gastroenterol. 2007 Dec;18(4):245-9
pubmed: 18080921
Cancer. 2002 Dec 15;95(12):2539-45
pubmed: 12467068
J Clin Lab Anal. 2010;24(3):195-200
pubmed: 20486202
Ann Hepatol. 2013 May-Jun;12(3):456-63
pubmed: 23619263
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Hepatol Int. 2007 Jun;1(2):287-94
pubmed: 19669352
Hepatology. 2000 Sep;32(3):679-80
pubmed: 10991637
Endocr Rev. 1995 Feb;16(1):3-34
pubmed: 7758431
Anticancer Res. 2004 Sep-Oct;24(5A):3029-34
pubmed: 15517912
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Cancer. 1985 Aug 15;56(4):918-28
pubmed: 2990661
Hepat Mon. 2013 Feb 23;13(2):e6181
pubmed: 23599716